A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma

Joao Paulo da Silveira Nogueira Lima1,*,†, Mina Georgieva2,†, Benjamin Haaland2 & Gilberto de Lima Lopes3

1Drug Development Unit, Institute of Cancer Research, Sutton, United Kingdom
2Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia
3Sylvester Comprehensive Cancer Center, Global Oncology Program, Miami, Florida

Keywords
Bayesian, biomarker, BRAF, immunotherapy, melanoma, meta-analysis

Abstract
Immune and BRAF-targeted therapies have changed the therapeutic scenario of advanced melanoma, turning the clinical decision-making a challenging task. This Bayesian network meta-analysis assesses the role of immunotherapies and targeted therapies for advanced melanoma. We retrieved randomized controlled trials testing immune, BRAF- or MEK-targeted therapies for advanced melanoma from electronic databases. A Bayesian network model compared therapies using hazard ratio (HR) for overall survival (OS), progression-free survival (PFS), and odds ratio (OR) for response rate (RR), along with 95% credible intervals (95% CrI), and probabilities of drugs outperforming others. We assessed the impact of PD-L1 expression on immunotherapy efficacy. Sixteen studies evaluating eight therapies in 6849 patients were analyzed. For OS, BRAF-MEK combination and PD-1 single agent ranked similarly and outperformed all other treatments. For PFS, BRAF-MEK combination surpassed all other options, including CTLA-4-PD-1 dual blockade hazard ratio (HR: 0.56; 95% CrI: 0.33–0.97; probability better 96.2%), whereas BRAF single agent ranked close to CTLA-4-PD-1 blockade. For RR, BRAF-MEK combination was superior to all treatments including CTLA-4-PD-1 (OR: 2.78; 1.18–6.30; probability better 97.1%). No OS data were available for CTLA-4-PD-1 blockade at the time of systematic review, although PFS and RR results suggested that this combination could also bring meaningful benefit. PD-L1 expression, as presently defined, failed to inform patient selection to PD-L1-based immunotherapy. BRAF-MEK combination seemed an optimal therapy for BRAF-mutated patients, whereas PD-1 inhibitors seemed optimal for BRAF wild-type patients. Longer follow-up is needed to ascertain the role of CTLA-4-PD-1 blockade. Immunotherapy biomarkers remain as an unmet need.

Introduction
Recent groundbreaking discoveries in tumor biology and immune surveillance have yielded effective molecularly targeted therapies and immune agents, changing the scenario from one of poor responses and short survival to a completely new reality of high response rates, prolonged disease control, and the possibility of talking of a cure for some patients [1–5]. Blocking the BRAF-MEK pathway—commonly hyperactive in melanoma—has proved worthwhile. A sizeable number of trials have shown that BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) improve clinical outcomes when compared to chemotherapy [6–12]. The role of the immune system in controlling melanoma is well established and immune checkpoint inhibitors have shown promise in reinvigorating the immune system, successfully showcasing the enormous potential of drugs that manipulate immune surveillance for the first time in oncology [13–17].
These positive results have opened new avenues in the treatment of melanoma patients and, as expected, added layers of complexity to management of patients with advanced disease. A number of studies have compared competing treatments to one another, but an overall ranking of possible interventions is lacking. The number of options has grown markedly and defining the best therapeutic plan for a particular patient is now a formidable task. This Bayesian network meta-analysis of randomized controlled trials aims to establish relative efficacy of immunotherapy, molecularly targeted therapies, and chemotherapy, either alone or in combination, in patients with advanced or metastatic melanoma with a view to support and improve the therapeutic decision-making process.

**Patients and Methods**

**Search strategy**

We searched PubMed, Embase, Clinicaltrials.gov, Cochrane Central Register of Controlled Trials, World Health Organization International Trial Registry, drugs at FDA, and Society of Melanoma Research, ASCO, ESMO, and ECCO meetings using a combination of broad terms related to melanoma and drug therapy, namely melan*, random*, immunotherapy, BRAF*, MEK*, and chemotherapy (full list of terms in appendix). References in recovered studies and relevant reviews were also screened. Databases were searched from their inception until December 21st 2015. No language restrictions were applied. We followed a predefined protocol (PROSPERO number CRD42016038618) in accordance with the PRISMA guideline for network meta-analysis.

**Study selection**

Two reviewers independently searched databases (JL, GL) and assessed eligibility of studies based on abstracts and full texts, resolving disagreements by consensus. Eligible studies were (1) randomized controlled trials enrolling patients with metastatic or advanced melanoma and describing outcomes of interest, (2) randomized patients to chemotherapy, targeted therapy against the BRAF/MEK axis or immunotherapy (not vaccine, viral therapy or biochemotherapy), and (3) BRAF and/or MEK inhibitor trial restricted inclusion to patients known to harbor BRAF mutations. Second-line BRAF-MEK inhibitor studies were eligible if the first-line therapy had not been BRAF-targeted therapy. Studies with insufficient follow-up (≤6 months) or comparing different chemotherapy regimens were excluded. In the case of duplicated publication on the same study, the most up-to-date data were used. We acknowledged that inclusion criterion (4) would exclude NRAS-mutated patients.

**Data extraction**

Two authors (MG, BH) independently retrieved data from randomized controlled trial (RCT) full publications and relevant appendices, guided by an extraction form (Data S1). Disagreements were resolved by consensus.

**Outcomes of interest**

Hazard ratios for overall survival (OS) and progression-free survival (PFS), and odds ratios for response rate (RR), were collected or calculated for all included RCTs. We abstracted data from original intention-to-treat multivariate analysis whenever possible; thus, avoiding those derived from landmark analysis or solely based on median comparisons. We adhered to the definition of progression and the criteria used by each trial [18].

**Data synthesis and statistical analysis**

Network meta-analysis was performed in a hierarchical Bayesian random-effects model, with relative efficacy measures, hazard and odds ratios, analyzed on the log-scale and random effects for study. The network framework allows for synthesizing direct and indirect evidence into a single effect size. Indirect comparisons can be obtained from estimates of trials with common arms. Samples from the posterior distribution of the parameters were generated via Markov Chain Monte Carlo implemented through JAGS within R (http://mcmc-jags.sourceforge.net/). Detailed description of the Bayesian meta-analysis model is provided in (Data S1).

We calculated posterior mean hazard and odds ratios for relative efficacy of each therapy, along with 95% credible intervals, 95% predictive intervals, and probabilities of each treatment being better (probability better) than a reference. Therapies which achieved the combined benchmarks (1) overall survival (OS) posterior mean HR ≤ 0.8 with probability better ≥ 80% as compared to chemotherapy, (2) PFS posterior mean HR ≤ 0.6 with probability better than chemotherapy ≥ 90%, and (3) response rate (RR) posterior mean OR ≥ 3.0 with probability better than chemotherapy ≥ 95% were deemed to have a meaningful benefit as compared to chemotherapy [19].

We tested the hypothesis that BRAF mutation status alters relative efficacy of immunotherapy. Interactions between BRAF mutation status and relative efficacies were incorporated in the model. We also tested the hypothesis that PD-L1 expression affects relative efficacy of immunotherapies CTLA-4-PD-1 dual blockade, PD-1 blockade...
and CTLA-4 blockage. We adhered to the trial definition of PD-L1 positivity.

Study-to-study heterogeneity was summarized using predictive intervals, which provide an interval in which the relevant comparative efficacy measure would be expected to fall for a new study. Ranking and probabilities were calculated based on predicted relative effects drawn from the posterior. Quality of studies was assessed via Cochrane Collaboration’s tool for assessing risk of bias in randomized trials [20]. Publication bias was graphically assessed via funnel plot.

Results

Systematic review and qualitative analysis

A total of 1750 published or presented titles and abstracts were screened. After duplicated review and discussion, 18 trials on 10 types of therapy, comprising 7596 patients, had their data extracted. All trials were multicentric and reported in English. A sizeable number of trials used chemotherapy (dacarbazine, paclitaxel or temozolomide) as control arm. Trials assessing BRAF-MEK dual blockade used BRAFi as control arm and restricted enrollment to patients harboring BRAF mutations. When dealing with trials comparing MEK-chemotherapy versus chemotherapy, we restricted the data to BRAF-mutated patients. No trial performed a head-to-head comparison of immunotherapy versus BRAFi. The majority of excluded randomized trials failed to use BRAFi or immunotherapy as active comparator.

Two trials have been omitted from the main analysis as they have not produced relevant data; one comparing dacarbazine to dacarbazine and ipilimumab and other comparing ipilimumab to ipilimumab and sargramostim (available upon request) [16, 21]. Hence, the main analysis gathered data from 16 trials with eight therapeutic nodes and 6849 patients [6–8, 10, 13–15, 22–36].

All included evidence was intention-to-treat, based on standard analyses, from studies with low risk of bias, according to the Cochrane risk of bias tool (Fig. S1). No sign of publication bias was found using the funnel plot (Fig. S2). The schematic flowchart of systematic review is presented online (Fig. S3). Table 1 summarizes the trials included in the main analyses.

Quantitative analysis

The 16 trials were grouped across eight therapeutic nodes (6849 patients) according to type of therapy: chemotherapy, CTLa-4 blockade (CTLa-4i), PD-1 blockade (PD-1i), BRAF inhibitors (BRAFi), MEK inhibitors (MEKi), dual BRAF-MEK inhibitors (BRAFi-MEKi), chemotherapy-MEKi, and dual CTLa-4-PD-1 inhibitors (CTLa-4i-PD-1i). Figure S4 describes the network design of treatments’ comparison. All standard chemotherapies (paclitaxel, temozolomide, dacarbazine) were gathered into a single therapeutic node (chemotherapy), with analogous collapse for PD-1 drugs (nivolumab and pembrolizumab). BRAFi or MEKi results are restricted to BRAF-mutated patients across all comparisons. Not all trials described all outcomes (Table 1).

Efficacy

Three therapies achieved meaningful benefit compared to chemotherapy: PD-1 blockade, BRAFi-MEKi combination, and BRAFi. As evidenced by comparing the prediction and confidence intervals for OS, PFS, and RR, study-to-study heterogeneity was present, but broadly had little impact on posterior ranking of treatments.

Overall survival

OS data were available for 12 (of 16) studies including 4817 patients. The results based on traditional pairwise meta-analysis and Bayesian network meta-analysis were aligned with no identifiable signal of inconsistency between indirect and direct approaches. Three therapies improved OS when compared to chemotherapy, BRAFi-MEKi combination (HR: 0.50; 95% CrI: 0.34–0.74; 95% Pri: 0.31–0.82), PD-1i (HR: 0.52; 95% CrI: 0.36–0.75; 95% Pri: 0.32–0.83), and BRAFi (HR: 0.71; 95% CrI: 0.51–0.97; 95% Pri: 0.46–1.09). PD-1i and BRAFi-MEKi performed similarly (HR: 1.03; 95% CrI: 0.60–1.76; 95% Pri: 0.56–1.90) with probability of BRAFi-MEKi being superior to PD-1i of 55.8%. Both BRAFi-MEKi and PD-1i had high posterior probability of outperforming all competitors. Full comparative OS results are provided in Figure 1. Given high probabilities of outperforming competitor therapies, for PFS and RR, BRAFi-MEKi combination may be optimal for BRAF-mutated patients, whereas PD-1i may be optimal for BRAF wild-type patients or selected BRAF-mutated patients.

Despite the lack of OS data for CTLa-4i-PD-1i combination at the time of systematic review, PFS and RR data were suggestive that CTLa-4i-PD-1i could also achieve meaningful benefit and consequently be a top-ranking option irrespective to BRAF status (see below) [14, 27].

Progression-free survival

Fifteen trials contributed to the PFS analysis. Worthy of note, the trial comparing tremelimumab (CTLa-4i) to chemotherapy provided 6-month time-restricted PFS data with tumor assessments done at different time points, every 6 weeks in the dacarbazine arm and every 12 weeks...
### Table 1. Main features of included trials—(A) BRAFi or MEKi trials and (B) Immunotherapy trials.

| Study Acronym | Population (line of therapy) | Treatments | N  | OS HR (95% CI) | PFS HR (95% CI) | Response (%) |
|---------------|------------------------------|------------|----|----------------|-----------------|--------------|
| BREAK-3[8, 24] | Unresectable stage III or IV BRAF | Dabrafenib 150 mg po bd | 187 | 0.77 (0.52–1.13) | 0.35 (0.20–0.61) | 93 (50) |
| NCT01006980 | V600E mutated (1st or 2nd) | DTIC<sup>4</sup> | 63 | Reference | Reference | 4 (6) |
| BRIM-3[16, 30] | Previously untreated metastatic BRAF | Vemurafenib 960 mg po bd | 337 | 0.70 (0.57–0.87) | 0.38 (0.32–0.46) | 192 (57) |
| NCT01006980 | V600E mutated (1st) | DTIC<sup>4</sup> | 338 | Reference | Reference | 29 (9) |
| BRF1[7, 22] | Metastatic, no previous BRAFi; BRAF mutated (1st, 2nd, 3rd) | Dabrafenib 150 mg po bd + trametinib 2 mg po od | 54 | 0.79 (0.49–1.27) | 0.39 (0.25–0.62) | 41 (76) |
| NCT01072175 | Dabrafenib 150 mg po bd + trametinib 1 mg po od | 54 | 0.96 (0.57–1.60) | 0.56 (0.37–0.87) | 27 (50) |
| NCT01072175 | Dabrafenib 150 mg po bd | 54 | Reference | Reference | 29 (54) |
| coBRIM[26, 28] | Previously untreated; unresectable stage III or IV; BRAF mutated (1st) | Vemurafenib 960 mg po bd + cobimetinib 60 mg po od 3 weeks on 1 week off | 247 | 0.70 (0.55–0.90) | 0.58 (0.46–0.72) | 172 (70) |
| NCT01689519 | NCT01689519 | Vemurafenib 960 mg po bd + placebo | 248 | Reference | Reference | 124 (50) |
| COMBi-d[9, 10] | Progression after ipilimumab (and BRAFi if BRAF mutated) (2nd or further) | Nivolumab 3 mg/kg iv every 2 weeks | 272 | – | – | 38 (32) |
| NCT01584648 | Previously untreated or BRAF mutated (1st) | Nivolumab 3 mg/kg iv every 2 weeks + DTIC<sup>4</sup>-placebo | 211 | 0.71 (0.55–0.92) | 0.67 (0.53–0.84) | 144 (68) |
| COMBi-<sup>4</sup>[34, 35] | Nivolumab 3 mg/kg iv every 2 weeks + placebo po od | 212 | Reference | Reference | 112 (53) |
| NCT01597908 | Previously untreated; metastatic; BRAF mutated (1st) | Dabrafenib 150 mg po bd + trametinib 2 mg po od | 352 | 0.66 (0.53–0.81) | 0.61 (0.51–0.73) | 226 (64) |
| METRIC[23, 29] | Nivolumab 960 mg po bd | 352 | Reference | Reference | 180 (51) |
| NCT01245062 | Vemurafenib 960 mg po bd + cobimetinib 60 mg po od | 214 | 0.54 (0.32–0.92) | 0.42 (0.29–0.59) | 47 (22) |
| NCT00338130[25] | Selumetinib 100 mg po bd continuously | 45 | 1.65 (0.91–3.01) | 1.24 (0.73–2.10) | 5 (11) |
| NCT00936221[33] | Selumetinib 75 mg po bd + DTIC<sup>4</sup> | 45 | 0.93 (0.57–1.53) | 0.63 (0.40–0.98) | 18 (40) |
| NCT00338130 | Selumetinib 100 mg po bd + placebo | 45 | Reference | Reference | 3 (11) |
| NCT00936221 | Selumetinib 75 mg po bd + DTIC<sup>4</sup> | 45 | 0.93 (0.57–1.53) | 0.63 (0.40–0.98) | 18 (40) |
| NCT01245062 | Placebo po bd + DTIC<sup>4</sup> | 46 | Reference | Reference | 12 (26) |
| CheckMate 037 | Progression after ipilimumab (and BRAFi if BRAF mutated) (2nd or further) | Nivolumab 3 mg/kg iv every 2 weeks | 272 | – | – | 38 (32) |
| NCT01721746[13] | Nivolumab 3 mg/kg iv every 2 weeks + DTIC-placebo | 210 | 0.42 (0.25–0.73) | 0.43 (0.34–0.56) | 84 (40) |
| CheckMate 066 | Previously untreated; unresectable, stage III or IV non-veal, BRAF wild type (1st) | Nivolumab 3 mg/kg iv every 2 weeks + DTIC<sup>4</sup> | 208 | Reference | Reference | 29 (14) |
| NCT01721772[15] | Nivolumab 3 mg/kg iv every 2 weeks + ipi-placebo | 316 | – | 0.57 (0.43–0.76) | 138 (44) |
| CheckMate 067 | Nivolumab 1 mg/kg + ipilimumab 3 mg/kg iv both every 3 weeks 4x then Nivolumab 3 mg/kg iv every 2 weeks | 314 | – | 0.42 (0.31–0.57) | 181 (58) |
| NCT01844505[27] | Ipilimumab 3 mg/kg + nivo-placebo iv every 3 weeks 4x then nivo-placebo iv every 2 weeks | 315 | – | Reference | 60 (19) |

(Continued)
### Table 1.

| Study Acronym | Population (line of therapy) | Treatments | N | OS HR (95% CI) | PFS HR (95% CI) | Response (%) |
|---------------|-----------------------------|------------|---|----------------|-----------------|-------------|
| CheckMate 069 | Previously untreated; unresectable, stage III or IV (1st) | Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg iv every 3 weeks 4x then Nivolumab 3 mg/kg iv every 2 weeks (BRAF wild type) Ipilimumab 3 mg/kg + Placebo iv every 3 weeks 4x then Placebo iv every 2 weeks (BRAF wild type) Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg iv every 3 weeks 4x then Nivolumab 3 mg/kg iv every 2 weeks (BRAF mutated) Ipilimumab 3 mg/kg + Placebo iv every 3 weeks 4x then Placebo iv every 2 weeks (BRAF mutated) | 72 | 3 | 0.40 (0.23–0.68) | 44 (61) |
| CheckMate 069 | | Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg iv every 3 weeks 4x then Nivolumab 3 mg/kg iv every 2 weeks (BRAF wild type) | 37 | – | Reference 4 (11) |
| CheckMate 069 | | Ipilimumab 3 mg/kg + Placebo iv every 3 weeks 4x then Placebo iv every 2 weeks (BRAF wild type) | 23 | – | 0.38 (0.15–1.00) | 12 (52) |
| CheckMate 069 | | Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg iv every 3 weeks 4x then Nivolumab 3 mg/kg iv every 2 weeks (BRAF mutated) | 10 | – | Reference 1 (10) |
| Keynote 002 | Progression after ipilimumab and BRAFi if BRAF mutated (2nd or 3rd) | Pembrolizumab 2 mg/kg iv every 2 weeks | 180 | – | 0.57 (0.45–0.73) | 38 (21) |
| Keynote 002 | | Pembrolizumab 10 mg/kg iv every 2 weeks | 181 | – | 0.50 (0.39–0.64) | 46 (25) |
| Keynote 002 | | DTIC4 or pacitaxel5 or temozolomide7 or carbotaxol8 | 179 | Reference | Reference 8 (4) |
| Keynote 006 | Unresectable stage III or IV (1st or 2nd) | Pembrolizumab 10 mg/kg iv every 2 weeks | 183 | 0.58 (0.41–0.84) | 0.55 (0.42–0.72) | 62 (34) |
| Keynote 006 | | Pembrolizumab 10 mg/kg iv every 3 weeks | 185 | 0.68 (0.47–0.96) | 0.50 (0.38–0.66) | 60 (33) |
| Keynote 006 | | Ipilimumab 3 mg/kg iv every 3 weeks 4x | 181 | Reference | Reference 22 (12) |
| Keynote-006 | | Ipilimumab 3 mg/kg + Placebo iv every 3 weeks 4x then Placebo iv every 2 weeks (BRAF mutated) | 10 | – | Reference 1 (10) |
| NCT00257205 | Previously untreated; unresectable stage III or IV (1st) | Tremelimumab 10 mg/kg every 90 days | 328 | 0.9 (0.75–1.07) | 0.94 (0.81–1.11) | 36 (11) |
| NCT00257205 | | Temozolomide7 or DTIC8 | 327 | Reference | Reference 32 (10) |

NCT, National Clinical Trial (NCT) number found on clinicaltrials.gov; N, number of enrolled patients; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; BRAFi, BRAF inhibitor; MEKi, MEK inhibitor; po, oral; od, once a day; bd, twice a day; iv, intravenously; ipi-placebo, placebo matched to ipilimumab; nivo-placebo, placebo matched to nivolumab.

1Included patients from randomized part (part C) of the trial.
2BRAF mutation-positive data extracted from subgroup analysis.
3Data available after systematic review and not included in the meta-analysis.
4DTIC: Dacarbazine 1000 mg/kg iv every 3 weeks.
5PaciTaxel: Paclitaxel 175 mg/m² every 3 weeks.
6Carbotaxol: Paclitaxel 175 mg/m² plus Carboplatin AUC 5 both iv every 3 weeks.
7Temozolomide: temozolomide 200 mg/m²/d 5 days ON every 28 days.
8Carbotaxol: Paclitaxel 225 mg/kg plus Carboplatin AUC 6 both iv every 3 weeks.
in the tremelimumab arm [31]. This study was not included in the PFS analysis.

Four therapies clearly stood better than chemotherapy: BRAFi-MEKi (HR: 0.22; 95% CrI: 0.16–0.31; 95% PrI: 0.14–0.34), CTLA-4i-PD-1i (HR: 0.39; 95% CrI: 0.25–0.6; 95% PrI: 0.23–0.66), BRAFi (HR: 0.39; 95% CrI: 0.29–0.52; 95% PrI: 0.26–0.59), and PD-1i (HR: 0.5; 95% CrI: 0.4–0.64; 95% PrI: 0.34–0.73). Single agent PD-1i and dual CTLA-4i-PD-1i, both outperformed CTLA-4i with corresponding posterior probability of 99.5% (HR: 0.53; CrI: 0.42–0.68) and 99.9% (HR: 0.42; CrI: 0.3–0.57). CTLA-4i had similar performance to chemotherapy (HR: 0.94; CrI: 0.67–1.31).

Dual BRAFi-MEKi yielded the best PFS results with at least 97.1% posterior probability of being superior to any other treatment: CTLA-4i-PD-1i (OR: 2.73; CrI: 1.18–6.3), CTLA-4i (OR: 17.2; CrI: 8.31–35.58), PD-1i (OR: 4.57; CrI: 2.24–9.31), MEKi (OR: 8.36; CrI: 3.32–22.04), and BRAFi (OR: 1.83; CrI: 1.37–2.45). For BRAF-mutated patients, the second best option was BRAFi. CTLA-4i-PD-1i dual checkpoint blockade had a 94.3% posterior probability of being superior to single agent PD-1i (OR: 1.68; 95% CrI: 0.99–2.84).

PD-L1 expression and BRAF mutational status as biomarkers of response to immunotherapy. The Bayesian network meta-analysis failed to identify any relevant impact of BRAF mutation status on efficacy of immunotherapy treatments for OS, PFS, or RR in all subsets sought. The hazard ratios, 95% credible and predictive intervals of BRAF-mutated and wild-type patients were superimposable, which negates any role of BRAF status as a predictor of benefit of immunotherapy (Appendix S1).

Two immunotherapy trials provided information on outcomes according to PD-L1 status [14, 27]. As the definitions of positive and negative tumor PD-L1 expression as well as the laboratory methods used to ascertain them were not homogenous across the two PD-L1 trials (Nivolumab: at least 5% of tumor cells with PD-L1 at any intensity at the membrane; Pembrolizumab: >1% tumor cells with membranous PD-L1 expression), we accepted the trials’ original cutoffs.

For both PFS and RR, the Bayesian network meta-analysis failed to show any relevant impact of PD-L1 status on efficacy of CTLA-4i-PD-1i, PD-1i, or CTLA-4i. The hazard ratios and 95% CrIs of PD-L1 positive and PD-L1 negative patients overlapped, failing to identify any

Response rate

RR data were available for all studies. Bearing in mind that response under CTLA-4i can be a late event, we included the tremelimumab versus chemotherapy trial in this analysis. Four therapies led to meaningful benefit (OR ≥ 3.0 and probability better ≥ 95% vs. chemotherapy): BRAFi-MEKi (HR: 19.76; 95% CrI: 10.45–37.35; 95% PrI: 9.19–42.52), BRAFi (HR: 10.78; 95% CrI: 6.24–18.63; 95% PrI: 5.4–21.48), CTLA-4i-PD-1i (HR: 7.25; 95% CrI: 4.09–12.86; 95% PrI: 3.57–14.7), and PD-1i (HR: 4.32; 95% CrI: 3.07–6.09; 95% PrI: 2.52–7.45). Full comparative RR results are presented in Figure 3.
difference according to PD-L1 status (Appendix S2). The posterior probability that PD-L1 positive patients had better efficacy under CTLA-4i-PD-1i, PD-1i, or CTLA-4i, (probability PD-L1+ better) was from 44% to 56% for PFS, and 62% to 83% for RR.

**Discussion**

This meta-analysis synthesizes the wealth of information on immunotherapy and BRAFi/MEKi for advanced melanoma, producing a ranking of the drugs currently available. The network approach attempts to circumvent the absence of direct comparisons among the many available options, notably the comparison of immunotherapy to BRAF- MEK inhibition and among immunotherapies. The present meta-analysis suggests that dual BRAFi-MEKi is the most effective in improving OS, PFS, and RR of BRAF-mutated patients, outperforming other treatments.

Among the BRAF-MEK axis inhibition options, single-agent BRAFi ranked below BRAFi-MEKi combination, but could still offer higher benefits than single MEKi. These findings may prompt inquiry into how to manage dose reduction of MEKi and BRAFi in the event of toxicities likely to be caused by both drugs. However, clinically relevant this question is, it is beyond the scope of our study to provide such practical guidance.

Appraising the PFS and RR scenarios, it was conceivable that BRAFi-MEKi would dominate them, as BRAF-MEK inhibition was already known to produce frequent and rapid responses, whereas immunotherapy may take longer to produce sustained tumor shrinkage and even lead to unconventional response patterns not properly captured by the standard response assessments [18, 37, 38]. CTLA-4i epitomized the immune response pattern: failed to improve PFS and RR when compared to chemotherapy, but prolonged OS, as the original trials suggested [16, 31]. Our findings underscore the perception that, standard PFS assessment may not be the best way to capture anti-tumor activity of immunotherapy. Nevertheless, it is noteworthy that dual BRAFi-MEKi also stood as the best option with regard to OS, even when compared to single-agent PD-1i.

Notwithstanding the BRAF-MEK inhibition dominance, PD-1 blockade still ranked high in terms of OS, PFS, and RR. Hence, PD-1i may be an attractive option for BRAF wild-type patients and even for BRAF-mutated patients, as it ranked in second to BRAFi-MEKi. OS results for combined CTLA-4-PD-1 immune checkpoint inhibition are not yet mature and longer follow-up may change the order of top-ranked therapies. Some very recent results have started to become available with promising long-term surviviorship with dual immune checkpoint blockade [39]. Those findings seem to embody the preliminary reports of prolonged disease control under immunotherapy [5].

We could not confirm the role of PD-L1 as a biomarker of response to PD-1i-based therapy. As currently tested, tumor PD-L1 expression did not better inform the patient selection for PD-1i-based therapy, both PD-L1 positive and negative patients derived substantial benefit from PD-1i-based therapy. This finding somewhat diverged from the realms of other tumors, showcasing the particular features of immune response within each tumor type [40]. Also, our results failed to show any impact of BRAF status
on response to PD-1 therapy, confirming previous find-

ings [41]. Several issues may be implicated on the lack of sur-

rogacy of PD-L1 expression. The simplest one would be

statistical power constrained by a small sample size. This

indeed could have played a role, however, more than 800

patients—evenly divided between PD-L1 positive and nega-

tive—provided data for this analysis. Another possibility

would be the use of inadequate cutoffs. To properly assess

this, individual patient data would be required. However,

even if such data were available, the different antibodies

and techniques would require careful consideration.

Harmonization of laboratory methods should be enacted

first, as is already occurring in lung cancer with the dif-

ferent PD-1/PD-L1 agents.

Lastly, baseline PD-L1 expression at a single tumor site

may not be capable of fully capturing the complexity of

anti-PD-1-led orchestration of immune system dynamics.

It is conceivable that resetting a whole system—in the

case of immune system—might be multilayered and con-

tinuously changing.

The quest for excellent patient selection is key. Better

patient selection transcends optimizing clinical outcomes.

It can improve financial resource allocation, a real-world

hurdle to be crossed when new technologies are under

consideration. Furthermore, identifying the most likely

patients for immunotherapy will spare the nonresponders

from fairly toxic therapies. The results of cooperative work

on other tumors may enhance our understanding on this

important topic [42–46].

A major clinical concern is the effectiveness of immu-
notherapy after progressing under previous BRAF-MEK

treatment. Two immunotherapy trials enrolled patients who

had progressed while on BRAF-targeted therapy [13, 32].

No sign of loss of efficacy was identified with the use of

PD-1 drug among this group of patients as compared to

BRAF therapy-naive patients. Such findings must be further

validated and the opposite drug order also appraised, the

latter being the question of active trials [48].

This meta-analysis faced several shortcomings inherent

to the methodology applied. We had no access to indi-


cidual patient data, precluding a more detailed appraisal

of outcomes and patients’ characteristics [49, 50]. We concen-

trated on efficacy foregoing analysis of toxicity, another major practical concern on

clinical grounds. The different cutoffs used for defining

PD-L1 status hindered a more robust analysis of its rel-


evance. The absence of overall survival data for CTLA-

4-PD-1 trials is a major shortcoming and hopefully more

data will become available in the near future [39]. Also,

for the sake of simplicity, we analyzed all drugs in the

same therapeutic node as identical (for instance

Figure 3. Response rate network meta-analysis. HR, hazard ratio; CI, credible interval; PI, Predictive interval; BRAF+BRAF-mutated patients; BRAF-

BRAF wild-type patients.

is another crucial question. The wealth of information

organized by this meta-analysis may shed light on the

long-term therapeutic plan for melanoma patients. These

nuances of clinical management are yet to be defined.

However, we believe that clinicians will now be better

informed for the decision-making process. Definitive results

on sequencing of the various therapeutic options will add

to the knowledge base [47, 48].

A major clinical concern is the effectiveness of immu-
notherapy after progressing under previous BRAF-MEK

treatment. Two immunotherapy trials enrolled patients who

had progressed while on BRAF-targeted therapy [13, 32].

No sign of loss of efficacy was identified with the use of

PD-1 drug among this group of patients as compared to

BRAF therapy-naive patients. Such findings must be further

validated and the opposite drug order also appraised, the

latter being the question of active trials [48].

This meta-analysis faced several shortcomings inherent

to the methodology applied. We had no access to indi-


cidual patient data, precluding a more detailed appraisal

of outcomes and patients’ characteristics. This is especially

true for assessment of the role of PD-L1 expression, vol-

ume of disease, and presence of other known prognostic

markers [49, 50]. We concentrated on efficacy foregoing

analysis of toxicity, another major practical concern on

clinical grounds. The different cutoffs used for defining

PD-L1 status hindered a more robust analysis of its rel-


evance. The absence of overall survival data for CTLA-

4-PD-1 trials is a major shortcoming and hopefully more

data will become available in the near future [39]. Also,

for the sake of simplicity, we analyzed all drugs in the

same therapeutic node as identical (for instance

Figure 3. Response rate network meta-analysis. HR, hazard ratio; CI, credible interval; PI, Predictive interval; BRAF+BRAF-mutated patients; BRAF-

BRAF wild-type patients.

is another crucial question. The wealth of information

organized by this meta-analysis may shed light on the

long-term therapeutic plan for melanoma patients. These

nuances of clinical management are yet to be defined.

However, we believe that clinicians will now be better

informed for the decision-making process. Definitive results

on sequencing of the various therapeutic options will add

to the knowledge base [47, 48].

A major clinical concern is the effectiveness of immu-
notherapy after progressing under previous BRAF-MEK

treatment. Two immunotherapy trials enrolled patients who

had progressed while on BRAF-targeted therapy [13, 32].

No sign of loss of efficacy was identified with the use of

PD-1 drug among this group of patients as compared to

BRAF therapy-naive patients. Such findings must be further

validated and the opposite drug order also appraised, the

latter being the question of active trials [48].

This meta-analysis faced several shortcomings inherent

to the methodology applied. We had no access to indi-


cidual patient data, precluding a more detailed appraisal

of outcomes and patients’ characteristics. This is especially

true for assessment of the role of PD-L1 expression, vol-

ume of disease, and presence of other known prognostic

markers [49, 50]. We concentrated on efficacy foregoing

analysis of toxicity, another major practical concern on

clinical grounds. The different cutoffs used for defining

PD-L1 status hindered a more robust analysis of its rel-


evance. The absence of overall survival data for CTLA-

4-PD-1 trials is a major shortcoming and hopefully more

data will become available in the near future [39]. Also,

for the sake of simplicity, we analyzed all drugs in the

same therapeutic node as identical (for instance

Figure 3. Response rate network meta-analysis. HR, hazard ratio; CI, credible interval; PI, Predictive interval; BRAF+BRAF-mutated patients; BRAF-

BRAF wild-type patients.
tremelimumab and ipilimumab as CTLA-4i prototypes). Furthermore, the duration of response could not be formally assessed as the original trials lacked enough information for a comprehensive appraisal.

Another concern was the publication and trial quality biases. We sought the most relevant databases in order to collect all published and presented trials so far, checked their references and references from relevant reviews and followed Cochrane’s guidelines on the topic. Also, we preplanned the inclusion of BRAFi or immunotherapy trials in order to concentrate on the most promising therapies; hence, some randomized trials testing other targeted therapies, such as sorafenib, oblimersen, or endothelin inhibitors were not meta-analyzed. Trials enrolling personalized therapy to other targets, such as NRAS-mutant tumor, were not included [51]. With regard to the quality of trials included, nearly all trials were ascribed as high quality according to the Cochrane risk of bias tool, with the lack of placebo as the commonest source of likely bias.

Furthermore, it is conceivable that gathering different drugs with different doses and regimens in the same node could lead to heterogeneity, and some heterogeneity was found among the several comparisons made. Nevertheless—and most importantly—direct comparison results were in line with the network results and the impact of heterogeneity on the ranking of therapy options was minimal.

In spite of all those shortcomings listed above, we were able to formally compare different therapies and provide a clear rank of efficacy of the many available options for advanced melanoma. Abstracting all this sizeable amount of information, combined BRAFi-MEKi-targeted therapy seems to be a sound option at the present—even in light of emerging results of immune therapy—for BRAF-mutant patients. Longer follow-up in dual immune checkpoint trials coupled with further analysis of immune markers have the potential to further enhance outcomes in advanced melanoma.

**Conflict of Interest**

None declared.

**References**

1. Eggermont, A. M., A. Spatz, and C. Robert. 2014. Cutaneous melanoma. Lancet 383:816–827.
2. Eigentler, T. K., U. M. Caroli, P. Radny, and C. Garbe. 2003. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 4:748–759.
3. Harriesa, M., J. Malvehyb, C. Lebbec, L. Herond, J. Amelioe, Z. Szabofof, et al. 2016. Treatment patterns of advanced malignant melanoma (stage-III-IV) - A review of current standards in Europe. Eur. J. Cancer 60:179–189.
4. Middleton, M. R., S. Dalle, J. Claveau, et al. 2016. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Med. 5:1436–1443.
5. Schadendorf, D., F. S. Hodi, C. Robert, et al. 2015. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33:1889–1894.
6. Chapman, P. B., A. Hauschild, C. Robert, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507–2516.
7. Flaherty, K. T., J. R. Infante, A. Daud, et al. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367:1694–1703.
8. Hauschild, A., J. I. Grob, L. V. Demidow, et al. 2012. Dabrafenib in BRAF mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365.
9. Long, G. V., D. Stroyakovskiy, H. Gogas, et al. 2014. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371:1877–1888.
10. Long, G. V., D. Stroyakovskiy, H. Gogas, et al. 2015. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444–451.
11. Schubbert, S., K. Shannon, and G. Bollag. 2007. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7:295–308.
12. Seton-Rogers, S. 2014. Therapeutics: delving deeper into resistance. Nat. Rev. Cancer 14:7.
13. Weber, J. S., S. P. D’Angelo, D. Minor, et al. 2015. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384.
14. Postow, M. A., J. Chesney, A. C. Pavlick, et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:2006–2017.
15. Robert, C., G. V. Long, B. Brady, et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320–330.
16. Robert, C., L. Thomas, I. Bondarenko, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517–2526.
17. Andtbacka, R. H., H. L. Kaufman, F. Collichio, et al. 2015. TalimogeneLaherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J. Clin. Oncol. 33:2780–2788.
18. Wolchok, J. D., A. Hoos, S. O’Day, et al. 2009. Guidelines for the evaluation of immune therapy
activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15:7412–7420.
19. Salanti, G., A. E. Ades, and J. P. Ioannidis. 2011. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64:163–171.
20. Higgins, J. P., D. G. Altman, P. C. Gotzsche, et al. 2011. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928.
21. Hodi, F. S., S. Lee, D. F. McDermott, et al. 2014. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744–1753.
22. Daud, A., J. S. Weber, J. A. Sosman, et al. 2015. Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). ASCO Meeting Abstracts 33:9036.
23. Flaherty, K. T., C. Robert, P. Hersey, et al. 2012. Improved survival with MEK inhibition in BRAF mutated melanoma. N. Engl. J. Med. 367:107–114.
24. Hauschild, A., J. Grobb, L. Demidov, et al. 2014. 1092PD an update on overall survival (OS) and follow-on therapies in break-3, a phase III, randomized trial: dabrafenib (D) vs. dacarbazine (DTIC) in patients (PTS) with braf V600E mutation-positive metastatic melanoma (MM). Ann. Oncol. 25:i378.
25. Kirkwood, J. M., L. Bastholt, C. Robert, et al. 2012. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18:555–567.
26. Larkin, J., P. A. Ascierto, B. Dreno, et al. 2014. Combined vemurafenib and cobimetinib in BRAF mutated melanoma. N. Engl. J. Med. 371:1867–1876.
27. Larkin, J., V. Chiarion-Sileni, R. Gonzalez, et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23–34.
28. Larkin, J. M. G., Y. Yan, G. A. McArthur, et al. 2015. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib ( vem) in advanced BRAF mutated melanoma. ASCO Meeting Abstracts33:9006.
29. Latimer, N. R., H. Bell, K. R. Abrams, M. M. Amonkar, and M. Casey. 2016. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 5:806–815.
30. McArthur, G. A., P. B. Chapman, C. Robert, et al. 2014. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15:323–332.
31. Ribas, A., R. Keeford, M. A. Marshall, et al. 2013. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31:616–622.
32. Ribas, A., I. Puzanov, R. Dummer, et al. 2015. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16:908–918.
33. Robert, C., R. Dummer, R. Gutzmmer, et al. 2013. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 14:733–740.
34. Robert, C., B. Karaszewska, J. Schachter, et al. 2014. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372:30–39.
35. Robert, C., B. Karaszewska, and J. Schachter, et al. 2015. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. In: European Cancer Congress 2015, Viena, abstract 3301.
36. Robert, C., J. Schachter, G. V. Long, et al. 2015. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372:2521–2532.
37. Simeone, E., G. Gentilcore, D. Giannarelli, et al. 2014. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol. Immunother. 63:673–683.
38. Hodi, F. S., W. J. Hwu, and R. Keeford, et al. 2016. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34:1510–1517.
39. Postow, M. A., J. Chesney, and A. Pavlick, et al. 2016. CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL). In: 2016 AACR annual meeting; 2016; New Orleans: AACR. p. CT002.
40. Aguiar, P. N., I. L. Santoro, H. Tadokoro, et al. 2016. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8:479–488.
41. Larkin, J., C. D. Lao, W. J. Urba, et al. 2015. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a
pooled analysis of 4 clinical trials. JAMA Oncol. 1:433–440.
42. Ratcliffe, M. J., A. Sharpe, A. Midha, C. Barker, P. Scorer, and J. Walker. 2016. A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative. In: AACR, editor. AACR annual meeting 2016; New Orleans: AACC; 2016. p. LBA-094.
43. Scheel, A. H., M. Dietel, L. C. Heukamp, et al. 2016. Diagnostic PD-L1 immunohistochemistry in NSCLC: results of the first German harmonization study. ASCO Meeting Abstracts 34:3028.
44. No authors listed. 2015. A blueprint proposal for companion diagnostic comparability FDA-AACR-ASCO, In. Washington.
45. Powles, T., J. P. Eder, G. D. Fine, et al. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562.
46. Tumeh, P. C., C. L. Harview, J. H. Yearley, et al. 2015. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571.
47. Ribas, A., M. Butler, J. Lutzky, et al. 2015. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. ASCO Meeting Abstracts 33:3003.
48. Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma. 2016. Available at: https://clinicaltrials.gov/ct2/show/study/NCT02224781 (Accessed 12 April 2016)
49. Diem, S., B. Kasenda, J. Martin-Liberal, et al. 2015. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur. J. Cancer 51:2785–2791.
50. Diem, S., B. Kasenda, L. Spain, et al. 2015. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114:256–261.
51. Dummer, R., D. Schadendorf, P. A. Ascierto, et al. 2016. Results of NEMO: A phase III trial of binimetinib (BNI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. ASCO Meeting Abstracts 34:9500.

Supporting Information

Additional supporting information may be found in the online version of this article:

Data S1. Full search strategy for PubMed.
Figure S1. Cochrane risk of bias tool.
Figure S2. Funnel plot of publication bias.
Figure S3. PRISMA flowchart of systematic review of studies included in the Bayesian network meta-analysis.
Figure S4. Network diagram of therapeutic nodes.

The area of the circle is proportional to the sample size of patients enrolled in each node; the width of connecting lines indicates the number of direct comparisons within trials. Chemo: chemotherapy; *: MEKi + chemotherapy; **: CTLA-4i-GMCSF; ***: CTLA-4-chemotherapy; Green circles: immunotherapy nodes; Orange circles: BRAFi or MEKi-based nodes; Blue circle: chemotherapy node.

Number of patients in each node: CTLA-4i: 1172; PD-1i: 1527; CTLA-4i-PD-1i: 409; CTLA-4-chemotherapy: 250; CTLA-4i-GMCSF: 123; MEKi single agent: 259; Chemotherapy: 804; BRAFi single agent: 1390; BRAFi + MEKi: 918; MEKi + chemotherapy: 45.

Appendix S1. Posterior probability that BRAF-mutated patients had better outcomes than BRAF wild type under immunotherapy.
Appendix S2. Posterior probability that PD-L1-positive patients had better outcomes on immunotherapy.